Navigation Links
Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
Date:6/24/2008

Durezol is First Ophthalmic Steroid Indicated for Inflammation and Pain

TAMPA, Fla., June 24 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved its new drug application for Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, a topical steroid for the treatment of postoperative ocular inflammation and pain. The approval came after a six month priority review.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )

"Durezol, our first product to be approved by the FDA, is a potent topical steroid that works rapidly and effectively to resolve postoperative inflammation and pain," said Barry Butler, President and CEO of Sirion Therapeutics, Inc. "We look forward to launching the first innovation in the strong steroid class in more than 35 years, and the first steroid to have an indication for the treatment of postoperative pain. We believe that having access to a steroid that treats both inflammation and pain gives physicians a more complete treatment approach."

In two Phase 3 trials evaluating Durezol in patients diagnosed with significant postoperative inflammation (more than 10 anterior chamber cells), Durezol rapidly reduced inflammation and pain. Mean intraocular pressure (IOP) for all study groups remained within the normal range throughout the study.

"Rapid resolution of inflammation and pain is very important following ocular surgery," said Dr. Michael Korenfeld, M.D., Assistant Clinical Professor of Ophthalmology and Visual Sciences, Washington University, St. Louis, MO, and principal investigator for the Phase 3 trials. "It is important to point out that in these Phase 3 studies, patients were dosed for the first time after the ocular trauma from surgery had occurred. The results from these studies, particularly the ability to eliminate postoperative pain demonstrate that Durezol is a powerful option for postoperative care."

Sirion Therapeutics plans to make Durezol commercially available in late 2008.

Phase 3 Program Results

The two U.S. Phase 3 multi-center studies evaluated the safety and efficacy of Durezol compared to placebo dosed twice a day (BID) and four times a day (QID) beginning 24 hours after intraocular surgery. Treatment occurred over 4 weeks and included tapering. The studies included 438 subjects who presented with significant inflammation as evidenced by an anterior chamber cell grade 2 or higher (greater than 10 cells) the day after surgery.

Both regimens (BID and QID) had similar overall efficacy in the reduction of anterior chamber cells two weeks following surgery (86% in BID and 87% in QID). The QID regimen had a small numerical advantage in the number of patients who were completely free of inflammation and pain at the one week time point. Because of this numerical advantage, and the desire to treat inflammation aggressively, the QID dosing regimen was chosen for recommendation to doctors.

Durezol was well tolerated with few treatment related adverse events. One of the most common side effects seen with steroids in ophthalmic use is a rise in IOP. Three percent of subjects in each of the BID and QID groups, and one percent of subjects in the placebo group met the criterion for a clinically significant rise in IOP, defined as an observed value of greater than or equal to 21 mm Hg and a change from baseline of 10 mm Hg.

About Postoperative Inflammation

More than five million ophthalmic surgeries are performed each year in the United States. Postoperative inflammation and pain are common occurrences following these procedures and if left untreated, can interfere with a patient's visual rehabilitation or lead to further complications. Corticosteroids and non-steroidal anti-inflammatory drugs are commonly used by healthcare professionals following ophthalmic surgery.

About Durezol

Durezol (difluprednate ophthalmic emulsion) 0.05% is a topical ophthalmic corticosteroid for the treatment of postoperative inflammation and pain associated ocular surgery. Durezol is a difluorinated derivative of prednisolone and has potent anti-inflammatory activity. Prior to U.S. approval, the efficacy and safety of Durezol in ocular inflammatory diseases had been demonstrated in an extensive preclinical and clinical program in Japan.

Two Phase 3b studies evaluating Durezol for the management of inflammation and pain after intraocular surgery have been completed in which Durezol treatment was initiated one day prior to surgery. Durezol is also being studied in other ocular inflammatory diseases, including a U.S. Phase 3 study evaluating Durezol for the treatment of anterior uveitis.

About Sirion Therapeutics, Inc.

Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development, and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion's product portfolio includes: Durezol, a topical steroid for postoperative inflammation and pain and in development for uveitis; ganciclovir, a topical antiviral in development for herpetic keratitis; cyclosporine, a topical immunomodulator in development for dry eye; and fenretinide, a first-in-class oral vitamin A binding protein antagonist in development for geographic atrophy associated with dry AMD. For more information, please visit http://www.siriontherapeutics.com .


'/>"/>
SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sirion Therapeutics Supports Ophthalmic Education
2. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (NYSE MKT: ISR), a medical technology company and innovator ... treatment of prostate, brain, lung, head and neck and ... second quarter and six months of fiscal 2016, which ... --> Revenue was $1.19 million for ... 31, 2015, a 12% increase compared to $1.07 million ...
(Date:2/10/2016)... 10, 2016  Matchbook, Inc., a company specializing ... biotech companies, announced today the appointment of ... Jim brings nearly 25 years of experience in ... spent nearly two decades in executive level roles ... at Genzyme and, most recently headed global logistics ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual ... is expecting to fill more than 100 tables for its annual event, which ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... expansion to their comprehensive training and support program, Sonalinkā„¢ remote monitoring. The inaugural ... procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU ...
Breaking Biology Technology:
(Date:2/8/2016)... 8, 2016 Worldcore ... presents innovation for clients, comfort and unbeatable security, ... --> Worldcore is the first ... clients, comfort and unbeatable security, with a Voice ... Worldcore is the first EU-regulated global ...
(Date:2/3/2016)... 4, 2016 --> --> ... M (105.0), up 1,187% compared with fourth quarter of 2014. ... 517.6 M (loss: 30.0). Earnings per share increased to SEK ... 537.4 M (neg: 74.7). , --> ... to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/3/2016)... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ... "Emotion Detection and Recognition Market by Technology ... Tools (Facial Expression, Voice Recognition and Others), ... Global forecast to 2020" report to ... ) has announced the addition of the ...
Breaking Biology News(10 mins):